Skip to main content

Management of COPD: Lets Just Pretend Older Patients Don't Exist



We have previously discussed on GeriPal how the exclusion of older persons from research has left us clueless about how to treat many of the most common conditions in older persons. (see here and here and here)

Well here we go again. A recent article in the New England Journal of Medicine on the management of COPD is a rather stunning example of how ignoring the health needs of older persons and not incorporating even the most rudimentary principles of Geriatric Medicine make a large and expensive clinical study virtually meaningless for the majority of patients with COPD.

COPD (sometimes referred to as emphysema or chronic bronchitis) is one of the most common diseases in older persons. Persons with COPD have reduced lung capacity which leads to decreased exertion tolerance and symptoms such as shortness of breath and coughing. Superimposed on chronic symptoms, persons with COPD have "exacerbations" characterized by acute worsening of symptoms such as shortness of breath. These exacerbations are very distressing to patients and often leads to hospitalization. The two primary risk factors for COPD are smoking and age. COPD is largely a Geriatric condition, and the prevalence goes up markedly with age. It is the 4th leading cause of hospitalization for those on Medicare.

The NEJM study addresses an important question about the best way to prevent these distressing exacerbations. Most patients with COPD take a bronchodilator, a medicine delivered by an inhaler, to manage symptoms and prevent exacerbations. But there are two different classes of long acting bronchdilators available--anticholinergics (such as tiotropium) and beta agonists (such as salmeterol). We have little idea of which class is better--and we often have to just guess which one to give to our patients. We see LOTS of patients with COPD in Geriatrics. By trying to learn which of these inhalers we should use in our patients, this study had the potential to answer an important question for this common and debilitating condition.

The insight that most persons with COPD are old should greatly inform this type of study. For example, almost no patients have just COPD. They often have many other medical problems, and these medical problems greatly impact the management of COPD. They impact whether patients will have an exacerbation, and whether they will need to be hospitalized. And they could impact the type of treatment one will choose, as the side effects of a medicine may have adverse impacts on these other conditions.

Also, once one recognizes that COPD patients are old, you begin to recognize that the most important outcomes of COPD are not just "lung outcomes" The impact of COPD on day to day functioning becomes crucial. Not considering basic measures of functioning in a study of COPD, such as the ability to walk up stairs or do basic activities of daily living, would be like not measuring the FEV1.

This study suggests that tiotropium works slighly better than salmeterol at preventing COPD exacerbations, reducing the risk of exacerbation by 10-20%. Unfortunately, the design of the study makes the result almost irrelevant to most persons with COPD who are old and have other medical problems in addition to their COPD.

Here are some reasons the study does little to innform the management of older persons with COPD:
  1. The age of patients enrolled was extremely young, and not representative of most persons who have COPD. The mean age of patients was only 63. There is no breakdown on the number of subjects in the older age ranges, but it appears there were few patients over the age of 75 and almost none over the age of 80.
  2. The study provides almost no information on other diagnoses these patients had, their functional status, or the impact of the two treatments on day to day functioning
  3. But the most serious issue are the exclusion criteria which seem absolutely absurd. These are not in the printed article, but only available in the on-line appendix. (Something this important should not be relegated to an appendix!) As you think about some of the exclusions, think about the vanishingly small number of persons with COPD for whom this study is relevant:

  • Exclusion: "Significant diseases other than COPD, i.e. disease or condition which, in the opinion of the investigator, may have put the patient at risk because of participation in the study or may have influenced either the results of the study or the patients’ ability to participate in the study" (Comment: Yes. Co-existing conditions may influence the outcomes of treatment for COPD. But real world patients have more than one disease. Exluding them from a study makes the study of questionable relevance to real world practice)
  • Exclusion: Patients with a known symptomatic prostatic hyperplasia or bladder neck obstruction. (Comment: Seems this would exclude most men over the age of 70, and virtually all over the age of 80.).
  • Exclusion: "Patients with severe cardiovascular disorders" ; patients with a history of myocardial infarction in the past year; patients with an admission for CHF in the past year. (Comment: The coexistence of COPD with heart disease, especially CHF is VERY common. This eliminates another big group of real world patients)
  • Exclusion: Patients with moderate or severe renal insufficiency (Creatine clearance less than 50 ml/min). (Comment: You've got to be kidding)
  • Exclusion: Patients with brittle/unstable diabetes. (Comment: Unstable is not defined. Many with COPD have diabetes with less than ideal control)
  • Exclusion: Patients with a history of and/or active alcohol or drug abuse (Comment: there is no valid reason to exclude those who have recovered from alcoholism or drug abuse. Many with ongoing problems can still be included)

These issues, especially the exclusions, prevent this study from informing the care of the vast majority of older persons with COPD (and as a result, the majority of all persons with COPD). This is unfortunate, because knowing which of these drugs should be used as first line therapy in older persons with COPD could have resulted in significant improvements in care. It is time for our leading medical journals, funding agencies, regulatory agencies, and the public to insist that clinical research be conducted in a way that signficantly informs the care of older patients.

by: Ken Covinsky

Comments

Dan Matlock said…
Wonderful discussion Ken. The frustrated tone (i.e. "You've got to be kidding") of this post creates a much clearer and more effective message than similar articles published in journals. Great use of the blogosphere to highlight an extremely important issue.

I can't believe the exclusions were in the appendix!
Anonymous said…
Thank you for the post. Real world applications are what front line physicians and medical teams need to know. Plus...as usual look at the tie-in's between the funding source and the board membership of the principal researchers...see details at
http://www.nejm.org/doi/full/10.1056/NEJMoa1008378?query=featured_home&
Eric Widera said…
Does it change your mind at all that out of 9293 individuals assessed for eligibility, only 909 withdrew during screening or did not meet entry criteria? It would have been helpful to the reasons why they were excluded (or how many of the 909 were excluded based on the investigators discretion.)
Is there a letter to the editor in the works? Seems appropriate.

This article is a must read for any learner trying to figure out how to critically appraise an article.
rachelmiller said…
What about how hard it is for our patients with COPD and dementia to even use these inhalers correctly? Have you seen the video on how to use SPIRIVA? It is a multi-step (4 step) process. Even arthritis without any cognitive impairment makes this no easy task!
Great point Rachel. This is something I am frequently talking to families and patients about with inhalers. Just because you spray it past your lips does not mean it was delivered nor effective. Would love to see an instructional video or slide deck explaining when it may be time to reconsider if these inhalers are useful.

Popular posts from this blog

The Future of Palliative Care: A Podcast with Diane Meier

There are few names more closely associated with palliative care than Diane Meier.  She is an international leader of palliative care, a MacArthur "genius" awardee, and amongst many other leadership roles, the CEO of the Center to Advance Palliative Care (CAPC).  We were lucky enough to snag Diane for our podcast to talk about everything we always wanted to ask her, including:
What keeps her up at night?Does palliative care need a national strategy and if so why and what would it look like?The history of CAPC and the leadership centersAdvice that she has for graduating fellows who want to continue to move palliative care forward as they start their new careersWhat she imagines palliative care will look like in 10 or 15 years?What is the biggest threat facing palliative care? So take a listen and if you want to dive a little deeper, here are two articles that we discussed during the podcast:
A National Strategy For Palliative Care. Health Affairs 2017Palliative Care Leadership…

Advance Care Planning before Major Surgery: A Podcast with Vicky Tang

This week's podcast is all about the intersection of geriatrics, palliative care, advanced care planning and surgery with our guest Dr. Vicky Tang.  Vicky is an assistant professor and researcher here at UCSF.  We talk about her local and national efforts focused on this intersection, including:
Her JAMA Surgery article that showed 3 out of 4 older adults undergoing high risk surgery had no advance care planning (ACP) documentation. Prehab clinics and how ACP fits into these clinicsThe Geriatric Surgery Verification Quality Improvement Program whose goal is to set the standards for geriatric surgical care including ACP discussions prior to surgeryHow frailty fits in and how to assess it (including this paper from JAGS on the value of the chair raise test) So take a listen and check out some of those links.  For those who want to take a deeper dive into how GeriPal and surgery fit together, check out these other podcasts: Zara Cooper on Trauma Surgery, Geriatrics, and Palliative Car…

The Dangers of Fleet Enemas

The dangers of oral sodium phosphate preparations are fairly well known in the medical community. In 2006 the FDA issued it’s first warning that patients taking oral sodium phosphate preparations are at risk for potential for acute kidney injury. Two years later, over-the-counter preparations of these drugs were voluntarily withdrawn by the manufacturers.  Those agents still available by prescription were given black box warnings mainly due to acute phosphate nephropathy that can result in renal failure, especially in older adults. Despite all this talk of oral preparations, little was mentioned about a sodium phosphate preparation that is still available over-the-counter – the Fleet enema.

Why Oral Sodium Phosphate Preparations Are Dangerous 

Before we go into the risks of Fleet enemas, lets spend just a couple sentences on why oral sodium phosphate preparations carry significant risks. First, oral sodium phosphate preparations can cause significant fluid shifts within the colon …